ヒクマ製薬は,利益の減少と貿易の懸念により1月以来の株式の25%の減少に伴い,CEOのリアド・ミシュラウィをサイド・ダルワザに置き換えました. Hikma Pharmaceuticals replaced CEO Riad Mishlawi with Said Darwazah amid a 25% share drop since January due to declining profits and trade worries.

ヒクマ製薬は,前CEOのリッド・ミシュローリを元CEOのダーワザ氏に取って代わった。 Hikma Pharmaceuticals has replaced CEO Riad Mishlawi with former CEO Said Darwazah, effective immediately, after its share price fell 25% since January due to declining profits and trade uncertainties. ミシュラウィは双方合意により辞任し、退職する予定です。 Mishlawi stepped down by mutual agreement and will retire. 会社の財政的指導は変わらないままであり,新たなイギリスの貿易取引は,NHSの医薬品消費の増加と引き換えにイギリスの製薬の輸出に係る関税をアメリカに廃止し,米国の貿易上の障壁や事業の潜在的な懸念を抑制する. The company’s financial guidance remains unchanged, and a new UK-US trade deal eliminates tariffs on UK pharmaceutical exports to the US in exchange for increased NHS spending on medicines, easing concerns over potential US trade barriers and operations.